Physicochemical characterization of felodipine-kollidon VA64 amorphous solid dispersions prepared by hot-melt extrusion

Journal of Pharmaceutical Sciences

Volumn 102, Issue 6, 2013, Pages 1915-1923

  Song, Yuejun ^a,b   Wang, Lianyan ^b   Yang, Ping ^a   Wenslow, Robert M ^c   Tan, Bo ^b   Zhang, Hailu ^b   Deng, Zongwu ^b  

^a SOOCHOW UNIVERSITY   (China)

^b SUZHOU INSTITUTE OF NANO TECH AND NANO BIONICS   (China)

^c Suzhou Industrial Park ^*  (China)

Author keywords

Amorphous; Hot melt extrusion; Molecular dispersion; Physicochemical properties; Solid dispersion; Solid state NMR; Solubility; Stabilization

Indexed keywords

CARBON 13; FELODIPINE; POVIDONE;

ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG BIOAVAILABILITY; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; GLASS TRANSITION TEMPERATURE; HUMIDITY; HYDROGEN BOND; MELTING POINT; NUCLEAR MAGNETIC RESONANCE; PHASE SEPARATION; PHYSICAL CHEMISTRY; SOLID STATE; X RAY POWDER DIFFRACTION;

EID: 84877923467     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23538     Document Type: Article

References (53)

1. Amidon GL, Lennernäs H, Shah VP, Crison JR. 1995. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12:413-420.
2. Babu NJ, Nangia A. 2011. Solubility advantage of amorphous drugs and pharmaceutical cocrystals. Cryst Growth Des 11:2662-2679.
3. Kipp JE. 2004. The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs. Int J Pharm 284:109-122.
4. Serajuddin ATM. 2007. Salt formation to improve drug solubility. Adv Drug Deliv Rev 59:603-616.
5. Challa R, Ahuja A, Ali J, Khar R. 2005. Cyclodextrins in drug delivery: An updated review. AAPS Pharm Sci Tech 6:E329-E357.
6. Vemuri S, Rhodes CT. 1995. Preparation and characterization of liposomes as therapeutic delivery systems: A review. Pharm Acta Helv 70:95-111.
7. Willart JF, Descamps M. 2008. Solid state amorphization of pharmaceuticals. Mol Pharm 5:905-920.
8. Rodríguez-Hornedo N. 2007. Cocrystals: Molecular design of pharmaceutical materials. Mol Pharm 4:299-300.
9. Vasconcelos T, Sarmento B, Costa P. 2007. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discov Today 12:1068-1075.
10. Janssens S, Van den Mooter G. 2009. Review: Physical chemistry of solid dispersions. J Pharm Pharmacol 61:1571-1586.
11. Shanbhag A, Rabel S, Nauka E, Casadevall G, Shivanand P, Eichenbaum G, Mansky P. 2008. Method for screening of solid dispersion formulations of low-solubility compounds-Miniaturization and automation of solvent casting and dissolution testing. Int J Pharm 351:209-218.
12. Vasanthavada M, Tong WQ, Joshi Y, Kislalioglu MS. 2005. Phase behavior of amorphous molecular dispersions II: Role of hydrogen bonding in solid solubility and phase separation kinetics. Pharm Res 22:440-448.
13. Bikiaris DN. 2011. Solid dispersions, Part I: Recent evolutions and future opportunities in manufacturing methods for dissolution rate enhancement of poorly water-soluble drugs. Expert Opin Drug Deliv 8:1501-1519.
14. Bikiaris DN. 2011. Solid dispersions, Part II: New strategies in manufacturing methods for dissolution rate enhancement of poorly water-soluble drugs. Expert Opin Drug Deliv 8:1663-1680.
15. Albers J, Alles R, Matthée K, Knop K, Nahrup JS, Kleinebudde P. 2009. Mechanism of drug release from polymethacrylate-based extrudates and milled strands prepared by hot-melt extrusion. Eur J Pharm Biopharm 71:387-394.
16. Lakshman JP, Cao Y, Kowalski J, Serajuddin ATM. 2008. Application of melt extrusion in the development of a physically and chemically stable high-energy amorphous solid dispersion of a poorly water-soluble drug. Mol Pharm 5:994-1002.
17. Nakamichi K, Nakano T, Yasuura H, Izumi S, Kawashima Y. 2002. The role of the kneading paddle and the effects of screw revolution speed and water content on the preparation of solid dispersions using a twin-screw extruder. Int J Pharm 241:203-211.
18. Nagapudi K, Jona J. 2008. Amorphous active pharmaceutical ingredients in preclinical studies: Preparation, characterization, and formulation. Curr Bioact Compd 4:213-224.
19. Dixon WT, Schaefer J, Sefcik MD, Stejskal EO, McKay RA. 1982. Total suppression of sidebands in CPMAS C-13 NMR. J Magn Reson 49:341-345.
20. Sakellariou D, Lesage A, Hodgkinson P, Emsley L. 2000. Homonuclear dipolar decoupling in solid-state NMR using continuous phase modulation. Chem Phys Lett 319:253-260.
21. 1 relaxation measurements. Mol Pharm 7:1667-1691.
22. Srčič S, Kerč J, Urleb U, Zupančič I, Lahajnar G, Kofler B, Šmid-Korbar J. 1992. Investigation of felodipine polymorphism and its glassy state. Int J Pharm 87:1-10.
23. Surov AO, Solanko KA, Bond AD, Perlovich GL, Bauer-Brandl A. 2012. Crystallization and polymorphism of felodipine. Cryst Growth Des 12:4022-4030.
24. Rollinger JM, Burger A. 2001. Polymorphism of racemic felodipine and the unusual series of solid solutions in the binary system of its enantiomers. J Pharm Sci 90:949-959.
25. 13C CP MAS NMR and DFT study of vascular-selective drugs felodipine and amlodipine. Chem Phys Lett 463:195-200.
26. Teberekidis VI, Sigalas MP. 2007. Theoretical study of hydrogen bond interactions of felodipine with polyvinylpyrrolidone and polyethyleneglycol. J Mol Struc THEOCHEM 803:29-38.
27. Vogt FG, Williams G. 2012. Analysis of a nanocrystalline polymer dispersion of ebselen using solid-state NMR, Raman microscopy, and powder X-ray diffraction. Pharm Res 29:1866-1881.
28. Van Eerdenbrugh B, Taylor LS. 2011. Application of mid-IR spectroscopy for the characterization of pharmaceutical systems. Int J Pharm 417:3-16.
29. Tang XC, Pikal MJ, Taylor LS. 2002. A spectroscopic investigation of hydrogen bond patterns in crystalline and amorphous phases in dihydropyridine calcium channel blockers. Pharm Res 19:477-483.
30. Konno H, Taylor LS. 2006. Influence of different polymers on the crystallization tendency of molecularly dispersed amorphous felodipine. J Pharm Sci 95:2692-2705.
31. Qi S, Belton P, Nollenberger K, Gryczke A, Craig D. 2011. Compositional analysis of low quantities of phase separation in hot-melt-extruded solid dispersions: A combined atomic force microscopy, photothermal Fourier-transform infrared microspectroscopy, and localised thermal analysis approach. Pharm Res 28:2311-2326.
32. Kestur US, Taylor LS. 2010. Role of polymer chemistry in influencing crystal growth rates from amorphous felodipine. CrystEngComm 12:2390-2397.
33. Taylor LS, Langkilde FW, Zografi G. 2001. Fourier transform Raman spectroscopic study of the interaction of water vapor with amorphous polymers. J Pharm Sci 90:888-901.
34. Karavas E, Ktistis G, Xenakis A, Georgarakis E. 2005. Miscibility behavior and formation mechanism of stabilized felodipine-polyvinylpyrrolidone amorphous solid dispersions. Drug Dev Ind Pharm 31:473-489.
35. Andrews GP, Abu-Diak O, Kusmanto F, Hornsby P, Hui Z, Jones DS. 2010. Physicochemical characterization and drug-release properties of celecoxib hot-melt extruded glass solutions. J Pharm Pharmacol 62:1580-1590.
36. D'Souza AJM, Schowen RL, Borchardt RT, Salsbury JS, Munson EJ, Topp EM. 2003. Reaction of a peptide with polyvinylpyrrolidone in the solid state. J Pharm Sci 92:585-593.
37. Patel JR, Carlton RA, Yuniatine F, Needham TE, Wu L, Vogt FG. 2012. Preparation and structural characterization of amorphous spray-dried dispersions of tenoxicam with enhanced dissolution. J Pharm Sci 101:641-663.
38. Fossheim R. 1986. Crystal structure of the dihydropyridine calcium antagonist felodipine. Dihydropyridine binding prerequisites assessed from crystallographic data. J Med Chem 29:305-307.
39. Zhao YY, Inbar P, Chokshi HP, Malick AW, Choi DS. 2011. Prediction of the thermal phase diagram of amorphous solid dispersions by Flory-Huggins theory. J Pharm Sci 100:3196-3207.
40. Van Krevelen DW, Te Nijenhuis K. 2009. Properties of polymers. 4th ed. Oxford, UK: Elsevier Scientific Publication.
41. Marsac PJ, Shamblin SL, Taylor LS. 2006. Theoretical and practical approaches for prediction of drug-polymer miscibility and solubility. Pharm Res 10:2417-2426.
42. Tian YW, Booth J, Meehan E, Jones DS, Li S, Andrews GP. 2013. Construction of drug-polymer thermodynamic phase diagrams using Flory-Huggins interaction theory: Identifying the relevance of temperature and drug weight fraction to phase separation within solid dispersions. Mol Pharm 10:236-248.
43. Karavas E, Georgarakis E, Sigalas MP, Avgoustakis K, Bikiaris D. 2007. Investigation of the release mechanism of a sparingly water-soluble drug from solid dispersions in hydrophilic carriers based on physical state of drug, particle size distribution and drug-polymer interactions. Eur J Pharm Biopharm 66:334-347.
44. Abiad MG, Gonzalez DC, Mert B, Campanella OH, Carvajal MT. 2010. A novel method to measure the glass and melting transitions of pharmaceutical powders. Int J Pharm 396:23-29.
45. Cherukuvada S, Nangia A. 2012. Fast dissolving eutectic compositions of two anti-tubercular drugs. Cryst Eng Comm 14:2579-2588.
46. Geppi M, Guccione S, Mollica G, Pignatello R, Veracini CA. 2005. Molecular properties of ibuprofen and its solid dispersions with Eudragit RL100 studied by solid-state nuclear magnetic resonance. Pharm Res 22:1544-1555.
47. Mollica G, Geppi M, Pignatello R, Veracini C. 2006. Molecular properties of flurbiprofen and its solid dispersions with Eudragit RL100 studied by high- and low-resolution solid-state nuclear magnetic resonance. Pharm Res 23:2129-2140.
48. 13C CP/MAS NMR spectroscopy and direct exponential curve resolution algorithm. J Am Chem Soc 121:11554-11557.
49. Six K, Verreck G, Peeters J, Brewster M, Van den Mooter G. 2004. Increased physical stability and improved dissolution properties of itraconazole, a class II drug, by solid dispersions that combine fast- and slow-dissolving polymers. J Pharm Sci 93:124-131.
50. 1H-NMR spin-lattice relaxation. Chem Pharm Bull 55:1227-1231.
51. Newman A, Engers D, Bates S, Ivanisevic I, Kelly RC, Zografi G. 2008. Characterization of amorphous API: Polymer mixtures using X-ray powder diffraction. J Pharm Sci 97:4840-4857.
52. Alonzo DE, Gao Y, Zhou D, Mo H, Zhang GGZ, Taylor LS. 2011. Dissolution and precipitation behavior of amorphous solid dispersions. J Pharm Sci 100:3316-3331.
53. Ilevbare GA, Liu HY, Edgar KJ, Taylor LS. 2013. Maintaining supersaturation in aqueous drug solutions: Impact of different polymers on induction times. Cryst Growth Des 13:740-751.